BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Koulova L, Alexandrescu D, Dutcher JP, O’Boyle KP, Eapen S, Wiernik PH. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. Am J Hematol. 2005;78:49-54. [PMID: 15609292 DOI: 10.1002/ajh.20243] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Caramazza D, Quintini G, Abbene I, Malato A, Saccullo G, Coco LL, Di Trapani R, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S. Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab: TTP AND RITUXIMAB. Transfusion 2010;50:2753-60. [DOI: 10.1111/j.1537-2995.2010.02763.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
2 Jasti S, Coyle T, Gentile T, Rosales L, Poiesz B. Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature. J Clin Apher 2008;23:151-6. [PMID: 18712712 DOI: 10.1002/jca.20172] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.8] [Reference Citation Analysis]
3 Manenti L, Gnappi E, Vaglio A, Allegri L, Noris M, Bresin E, Pilato FP, Valoti E, Pasquali S, Buzio C. Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature. Nephrology Dialysis Transplantation 2013;28:2246-59. [DOI: 10.1093/ndt/gft220] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
4 Brocklebank V, Kavanagh D. Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea. Clin Kidney J 2017;10:600-24. [PMID: 28980670 DOI: 10.1093/ckj/sfx081] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
5 Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, Mackie I, Machin SJ. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol 2007;136:451-61. [PMID: 17233847 DOI: 10.1111/j.1365-2141.2006.06448.x] [Cited by in Crossref: 187] [Cited by in F6Publishing: 157] [Article Influence: 13.4] [Reference Citation Analysis]
6 Zhou Z, Yang R. Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Critical Reviews in Oncology/Hematology 2008;65:21-31. [DOI: 10.1016/j.critrevonc.2007.06.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
7 Park YW, Pryshchep S, Seyler TM, Goronzy JJ, Weyand CM. B cells as a therapeutic target in autoimmune diseases. Expert Opinion on Therapeutic Targets 2005;9:431-45. [DOI: 10.1517/14728222.9.3.431] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
8 Barcellini W, Zanella A. Rituximab therapy for autoimmune haematological diseases. Eur J Intern Med. 2011;22:220-229. [PMID: 21570637 DOI: 10.1016/j.ejim.2010.12.016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
9 Tun NM, Villani GM. Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. J Thromb Thrombolysis 2012;34:347-59. [DOI: 10.1007/s11239-012-0723-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
10 Cataland SR, Wu HM. Immunotherapy for thrombotic thrombocytopenic purpura: . Current Opinion in Hematology 2005;12:359-63. [DOI: 10.1097/01.moh.0000170534.33517.99] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
11 Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: A case series. Arthritis Rheum 2007;57:538-42. [DOI: 10.1002/art.22629] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
12 Dierickx D, De Rycke A, Vanderschueren S, Delannoy A. New treatment options for immune-mediated hematological disorders. European Journal of Internal Medicine 2008;19:579-86. [DOI: 10.1016/j.ejim.2007.08.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Scully M. Inhibitory anti-ADAMTS 13 antibodies: Measurement and clinical application. Blood Reviews 2010;24:11-6. [DOI: 10.1016/j.blre.2009.11.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
14 Caramazza D, Quintini G, Abbene I, Coco LL, Malato A, Di Trapani R, Saccullo G, Pizzo G, Palazzolo R, Barone R, Mazzola G, Rizzo S, Ragonese P, Aridon P, Abbadessa V, Siragusa S. Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome. Blood Transfus 2010;8:203-10. [PMID: 20671883 DOI: 10.2450/2009.0101-09] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
15 Garvey B. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol 2008;141:149-69. [DOI: 10.1111/j.1365-2141.2008.07054.x] [Cited by in Crossref: 152] [Cited by in F6Publishing: 113] [Article Influence: 11.7] [Reference Citation Analysis]
16 Jarasvaraparn C, Imran H, Siddiqui A, Wilson F, Gremse DA. Association of autoimmune hepatitis type 1 in a child with Evans syndrome. World J Hepatol 2017;9:1008-12. [PMID: 28878866 DOI: 10.4254/wjh.v9.i23.1008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
17 Diaz GC, Prowda J, Lo IJ, Arepally GM, Evans N, Wheeless Y, Samstein B, Guarrera JV, Renz JF. Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors: Transplantation-Mediated Alloimmune Thrombocytopenia. Liver Transpl 2008;14:1803-9. [DOI: 10.1002/lt.21539] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
18 Tuncer HH, Oster RA, Huang ST, Marques MB. Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience. Transfusion 2007;47:107-14. [DOI: 10.1111/j.1537-2995.2007.01071.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
19 Godeau B, Provan D, Bussel J. Immune thrombocytopenic purpura in adults: . Current Opinion in Hematology 2007;14:535-56. [DOI: 10.1097/moh.0b013e3282b9748f] [Cited by in Crossref: 58] [Cited by in F6Publishing: 10] [Article Influence: 4.1] [Reference Citation Analysis]
20 Ozdogu H, Boga C, Kizilkilic E, Yeral M, Kozanoglu I, Karatas M. A dramatic response to rituximab in a patient with resistant thrombotic thrombocytopenic purpura (TTP) who developed acute stroke. J Thromb Thrombolysis 2007;23:147-50. [DOI: 10.1007/s11239-006-9051-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
21 George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apheresis 2006;21:49-56. [DOI: 10.1002/jca.20091] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
22 Santos ES, Arosemena LR, Raez LE, O'brien C, Regev A. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int 2006;26:625-9. [DOI: 10.1111/j.1478-3231.2006.01262.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 3.2] [Reference Citation Analysis]
23 Garcia-Chavez J, Majluf-Cruz A, Montiel-Cervantes L, Esparza MG, Vela-Ojeda J; Mexican Hematology Study Group. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. Ann Hematol 2007;86:871-7. [PMID: 17874322 DOI: 10.1007/s00277-007-0317-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
24 Taylor RM, Bockenstedt P, Su GL, Marrero JA, Pellitier SM, Fontana RJ. Immune thrombocytopenic purpura following liver transplantation: a case series and review of the literature. Liver Transpl 2006;12:781-91. [PMID: 16628698 DOI: 10.1002/lt.20715] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
25 Dierickx D, Delannoy A, Saja K, Verhoef G, Provan D. Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders. Am J Hematol 2011;86:278-91. [DOI: 10.1002/ajh.21939] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]